Rosuvastatin is a selective and competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the rate limiting enzyme in the synthesis of cholesterol. Thus it inhibits the endogenous production of cholesterol in liver and reduces the concentration of cholesterol in blood. It also increases the number of hepatic LDL receptors on the cell-surface to enhance uptake and breakdown of LDL. Thus Rosvin is effective in the treatment of Hypercholesterolemia, in slowing the Progression of Atherosclerosis and in the Primary Prevention of Cardiovascular Disease

Hyperlipidemia and Mixed Dyslipidemia
Hypertriglyceridemia
Slowing of the Progression of Atherosclerosis
Primary Prevention of Cardiovascular Disease

Patients with a known hypersensitivity to any component of this product, with active liver disease, Women who are pregnant or may become pregnant, nursing mothers.

Rosuvastatin is generally well tolerated. Adverse events like headache, myalgia, constipation, asthenia, abdominal pain, and nausea has been reported.

Rosvin 5 is available as a strip of 10 tablets.

Rosuvastatin is a selective and competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the rate limiting enzyme in the synthesis of cholesterol. Thus it inhibits the endogenous production of cholesterol in liver and reduces the concentration of cholesterol in blood. It also increases the number of hepatic LDL receptors on the cell-surface to enhance uptake and breakdown of LDL. Thus Rosvin is effective in the treatment of Hypercholesterolemia, in slowing the Progression of Atherosclerosis and in the Primary Prevention of Cardiovascular Disease

Hyperlipidemia and Mixed Dyslipidemia
Hypertriglyceridemia
Slowing of the Progression of Atherosclerosis
Primary Prevention of Cardiovascular Disease

Patients with a known hypersensitivity to any component of this product, with active liver disease, Women who are pregnant or may become pregnant, nursing mothers.

Rosuvastatin is generally well tolerated. Adverse events like headache, myalgia, constipation, asthenia, abdominal pain, and nausea has been reported.

Rosvin 10 is available as a strip of 10 tablets.

Rosuvastatin is a selective and competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the rate limiting enzyme in the synthesis of cholesterol. Thus it inhibits the endogenous production of cholesterol in liver and reduces the concentration of cholesterol in blood. It also increases the number of hepatic LDL receptors on the cell-surface to enhance uptake and breakdown of LDL. Thus Rosvin is effective in the treatment of Hypercholesterolemia, in slowing the Progression of Atherosclerosis and in the Primary Prevention of Cardiovascular Disease

Hyperlipidemia and Mixed Dyslipidemia
Hypertriglyceridemia
Slowing of the Progression of Atherosclerosis
Primary Prevention of Cardiovascular Disease

Patients with a known hypersensitivity to any component of this product, with active liver disease, Women who are pregnant or may become pregnant, nursing mothers.

Rosuvastatin is generally well tolerated. Adverse events like headache, myalgia, constipation, asthenia, abdominal pain, and nausea has been reported.

Rosvin 20 is available as a strip of 10 tablets.

Mixed dyslipidaemia among patients with metabolic syndrome or diabetes mellitus is very common. Diabetic dyslipidaemia is characterized by increased low-density lipoprotein cholesterol (LDL-C), elevated triglycerides and low high-density lipoprotein cholesterol (HDL-C), is associated with an increased risk of coronary artery disease (CAD). Rosuvastatin in Rosvin- F significantly reduces LDL-C & increase HDL. Fenofibrate reduces triglycerides level and increases HDL level. Thus, the combination of rosuvastatin and fenofibrate offers an improved and effective therapeutic option in the management of diabetic dyslipidemia.

• In the management of Diabetic Dyslipidemia

Hypersensitivity to any ingredient of this formulation, Gall bladder disease, Pregnancy and breast feeding. In patients with hepatic or severe renal dysfunction.

Statins with fibrates can cause various muscular side effects including myalgia, myositis; gastrointestinal disturbances, anorexia, headache fatigue, renal impairment, arthralgia have been also reported.

ROSVIN – F is available as a strip of 10 tablets.

Mixed dyslipidaemia among patients with metabolic syndrome or diabetes mellitus is very common. Diabetic dyslipidaemia is characterized by increased low-density lipoprotein cholesterol (LDL-C), elevated triglycerides and low high-density lipoprotein cholesterol (HDL-C), is associated with an increased risk of coronary artery disease (CAD). Rosuvastatin in Rosvin- F significantly reduces LDL-C & increase HDL. Fenofibrate reduces triglycerides level and increases HDL level. Thus, the combination of rosuvastatin and fenofibrate offers an improved and effective therapeutic option in the management of diabetic dyslipidemia.

• In the management of Diabetic Dyslipidemia

Hypersensitivity to any ingredient of this formulation, Gall bladder disease, Pregnancy and breast feeding. In patients with hepatic or severe renal dysfunction.

Statins with fibrates can cause various muscular side effects including myalgia, myositis; gastrointestinal disturbances, anorexia, headache fatigue, renal impairment, arthralgia have been also reported.

One tablet once daily.

ROSVIN – F5 is available as a strip of 10 tablets.